ResearchDifferential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition
ResearchThe Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity
ResearchEfficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
ResearchRole of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer
ResearchObesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis
ResearchImmune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes
ResearchCharacteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients